Clinical trials: Empagliflozin
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
- Trial name
- NCT01734785
- Testing
- Linagliptin, Empagliflozin + Linagliptin
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 607 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, Dyslipidemias
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
- Trial name
- NCT06578676
- Testing
- Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Healthy
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo
- Trial name
- NCT01195675
- Testing
- BI 10773 (low), Moxifloxacin, BI 10773 (high)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
- Trial name
- NCT07102719
- Testing
- HD-P023, Teneligliptin and Empagliflozin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Empa PASS on Urinary Tract Malignancies
The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.
- Trial name
- NCT03464045
- Testing
- empagliflozin, DPP-4 inhibitors
- Where
- 3 sites in Finland, Sweden and 1 more
- Volunteers
- 344,995 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
the pharmacokinetics, pharmacodynamics and safety and tolerability of single and multiple oral doses of BI 10773 at low dose once daily (q.d.) and high dose q.d.
- Trial name
- NCT01316341
- Testing
- BI10773
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 304 (NCT05504239)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Handok Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic…
- Trial name
- NCT01368081
- Testing
- Metformin, BI 10773
- Where
- 87 sites in Japan
- Volunteers
- 1,162 people
- Sponsor
- Boehringer Ingelheim
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Atenas association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- ATENAS (NCT05144360)
- Testing
- Atenas
- Sponsor
- EMS
Type II Diabetes
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus
- Trial name
- PIEMONTE (NCT05028140)
- Testing
- PIEMONTE, EMPAGLIFLOZIN, PIOGLITAZONE
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- EMS
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic…
- Trial name
- NCT01984606
- Testing
- Empagliflozin, Sitagliptin
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- NCT06232239
- Testing
- Empagliflozin-Test product, Empagliflozin-Reference product
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Healthy
Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 10773 administered to healthy Japanese male subjects with single rising oral doses (1, 5, 10, 25, and 100 mg).
- Trial name
- NCT02182453
- Testing
- BI 10773 - single rising dose
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC019 (NCT07633028)
- Testing
- Empagliflozin/metformin 12.5/850 mg tablet (test), Synjardy 12.5/850 mg tablet (Reference)
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Healthy
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and bioequivalence of empagliflozin/metformin…
- Trial name
- NCT01811953
- Testing
- Empagliflozin, Metformin, Empagliflozin/Metformin
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when…
- Trial name
- NCT06083675
- Testing
- Semaglutide, Empagliflozin, Metformin
- Where
- 100 sites in United States, Brazil and 11 more
- Sponsor
- Novo Nordisk A/S